This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Positive Results Presented From Proof-of-Concept Phase II Clinical Trial Of Incyte's Oral JAK1 Inhibitor In Patients With Myelofibrosis

Incyte Corporation (Nasdaq: INCY) announced results of an interim analysis from a 12-week open-label, dose-escalation Phase II clinical trial involving more than 85 patients with intermediate or high-risk myelofibrosis (MF) for its proprietary oral JAK1 inhibitor, INCB39110. These results were presented today at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans.

In this preliminary analysis of an ongoing Phase II trial that involved three doses (100 mg twice daily, 200 mg twice daily and 600 mg once daily), treatment with INCB39110 at doses of 200 mg twice daily and 600 mg once daily provided meaningful improvements in MF-related symptoms, including symptoms associated with splenomegaly. At week 12, 22.2 percent, 34.9 percent, and 50.0 percent of patients in the 100 mg twice daily, 200 mg twice daily, and 600 mg once daily dose groups, respectively, achieved at least a 50 percent improvement from baseline in their total symptom score (the primary endpoint); median percentage improvements from baseline at this time point were 28.5 percent, 45.8 percent, and 76.8 percent, respectively, across dose groups. Reductions in spleen volume were modest, with median percentage changes from baseline to week 12 of 5.0 percent, -14.1 percent, and -9.9 percent, respectively, across dose groups. The most common hematologic adverse events, regardless of causality, were anemia and thrombocytopenia, and the most common non-hematologic adverse events were fatigue, constipation and nausea. In comparison to JAK1/JAK2 inhibitors and JAK2 inhibitors, the findings from this analysis suggest that JAK1 inhibition may result in less myelosuppression. In patients not receiving post-baseline transfusions, mean hemoglobin levels in each dose group increased by week 2 and remained approximately 0.5 to 1.0 g/dL above baseline through week 12.

To access the presentation: ASH 2013 - Mascarenhas

“With the interim analysis of this trial combined with data from two other proof-of-concept trials in rheumatoid arthritis and psoriasis, we have a better understanding of JAK1 as a disease target, and we’re using this knowledge to focus the development of our broad portfolio of JAK1 inhibitors,” stated Richard S. Levy, M.D., Incyte’s Executive Vice President and Chief Drug Development and Medical Officer. “We are taking INCB39110, our most advanced JAK1 inhibitor, forward initially in solid tumors, starting with combinations that may not be as well-tolerated with a JAK1/JAK2 inhibitor as a result of the potential myelosuppressive effect of JAK2 inhibition.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs